Swiss National Bank
BBIO icon

Swiss National Bank’s BridgeBio Pharma BBIO Stock Holding History

Swiss National Bank’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Buy
294,600
+8,600
+3% +$602K 0.01% 661
2026
Q1 		$21.2M Buy
286,000
+3,400
+1% +$246K 0.01% 641
2025
Q4 		$21.6M Buy
282,600
+6,600
+2% +$433K 0.01% 636
2025
Q3 		$14.3M Buy
276,000
+21,600
+8% +$1.05M 0.01% 780
2025
Q2 		$11M Buy
254,400
+16,400
+7% +$596K 0.01% 872
2025
Q1 		$8.23M Sell
238,000
-2,300
-1% -$77.6K 0.01% 990
2024
Q4 		$6.59M Buy
240,300
+21,000
+10% +$543K ﹤0.01% 1155
2024
Q3 		$5.58M Buy
219,300
+2,400
+1% +$63K ﹤0.01% 1263
2024
Q2 		$5.49M Buy
216,900
+10,900
+5% +$298K ﹤0.01% 1218
2024
Q1 		$6.37M Buy
206,000
+29,900
+17% +$1.02M ﹤0.01% 1145
2023
Q4 		$7.11M Sell
176,100
-18,000
-9% -$541K 0.01% 1073
2023
Q3 		$5.12M Buy
194,100
+2,300
+1% +$65.3K ﹤0.01% 1260
2023
Q2 		$3.3M Buy
191,800
+46,600
+32% +$701K ﹤0.01% 1574
2023
Q1 		$2.41M Sell
145,200
-15,900
-10% -$185K ﹤0.01% 1723
2022
Q4 		$1.23M Buy
161,100
+4,600
+3% +$44K ﹤0.01% 2232
2022
Q3 		$1.56M Hold
156,500
– – ﹤0.01% 2044
2022
Q2 		$1.42M Buy
156,500
+17,300
+12% +$145K ﹤0.01% 2153
2022
Q1 		$1.41M Sell
139,200
-9,300
-6% -$95.4K ﹤0.01% 2230
2021
Q4 		$2.48M Hold
148,500
– – ﹤0.01% 1914
2021
Q3 		$6.96M Buy
148,500
+800
+0.5% +$42.9K ﹤0.01% 1227
2021
Q2 		$9M Buy
147,700
+28,400
+24% +$1.62M 0.01% 1069
2021
Q1 		$7.35M Buy
+119,300
New +$7.8M ﹤0.01% 1205

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Swiss National Bank's BBIO Position: Q2 2026 in Review

Swiss National Bank increased its BridgeBio Pharma (BBIO) stake by 3% in Q2 2026, buying an estimated $602K and bringing the position to 294,600 shares worth $21.9M. The position accounts for 0.01% of the portfolio, ranked #661.

Swiss National Bank first reported a position in BBIO in Q1 2021 and has held it in 22 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Swiss National Bank held 294,600 shares of BridgeBio Pharma worth $21.9M as of Q2 2026.
  • Swiss National Bank bought 8,600 BridgeBio Pharma shares in Q2 2026, an estimated $602K.
  • BridgeBio Pharma made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #661 holding.
  • Swiss National Bank first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 22 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.